Bloxivir

After applying on the mucous membranes of the nose, mouth and throat, Bloxivir creates a coating that constitutes a mechanical barrier for pathogens, and the substances contained in it: iota-carrageenan, sodium hyaluronate and ectoine inactivate them. Thus, Bloxivir protects against highly contagious viruses, alleviates the symptoms of infection and reduces its duration. Thus, it is both a way of prevention and a way of fighting viral infections of the upper respiratory tract, caused by influenza viruses and coronaviruses including SARS-CoV-2. The use of the product by infected persons (also asymptomatic patients), reduces the risk of infecting others.

After the application on the mucous membranes of the nose, mouth and throat, Bloxivir creates a coating that constitutes a mechanical barrier for the virus of a coronavirus type, and the substances contained in it: iota-carrageenan, sodium hyaluronate and ectoine inactivate them. Thus, Bloxivir protects against the Sars-Cov-2 virus.

Bloxivir can be used both preventively and therapeutically. Preventive use of the product according to the method of use described in the instructions for use protects against the penetration of viruses into the body.

The device works directly at the site where viruses enter human cells. However, the likelihood of viral infection depends on individual factors and is higher if the mucous membrane of the nose or mouth is damaged or in the case of elderly people who suffer from dry mouth and nose. Covid-19 infection can also occur through the mucous membrane of the eyes.

The intended use of the product allows to improve the quality of life by preventing viral infections and mitigating their course. The product has bioadhesive properties and thus provides relief from symptoms of dryness in the nasal and oral mucosa, which results in its better functioning. Constant maintenance of good hydration of the nasal mucosa enables its efficient functioning as a natural protective barrier against pathogens and other external factors.   Therefore, the use of BLOXIVIR reduces the likelihood of Covid-19 infection but does not provide 100% protection due to individual factors.

The product alleviates symptoms of upper respiratory tract infections and supports treatment of those infected. If a person with Covid-19 has symptoms typical of upper respiratory tract infections such as nasal mucositis, rhinitis, runny nose, pharyngitis, dry throat then the use of Bloxivir will relieve the symptoms of the disease.

When the product is applied to the oral mucosa, a mechanical layer is formed and the protective effect begins immediately after the application. The protective layer remains in place despite contact with saliva, according to the instructions for use do not rinse the mouth for about 5 - 10 minutes.

Upper respiratory viruses, including Covid-19 can enter the human body through three routes:

• via the nasal mucosa (leading route)
• via the oral mucosa
• via the ocular mucosa.

When using Bloxivir in the form of a nasal spray we protect ourselves from the penetration of viruses into the body through the nose.

Yes, Bloxivir protects against the spread of the virus by reducing transmission from symptomatic or asymptomatic infected persons to others.

Yes, so as to preserve the microbiological environment in the packaging of the product for the declared shelf life, i.e. 2 years, and after opening the packaging (multi-dose packaging), a preservative system has been used in the product, commonly used in medicinal products, characterised by a broad spectrum of antimicrobial activity, low toxicity, good stability and low volatility.

The content of the preservative system in the product is safe and confirmed by the results of biological tests.

In accordance with the Regulation of the Minister of Health of 10 March 2011 on detailed conditions to be met by clinical evaluation of medical devices or active implantable medical devices (Journal of Laws of 2011, no. 63, item 331) clinical evaluation for the product Bloxivir was performed. The evaluation proves that there is sufficient clinical and non-clinical evidence that demonstrates compliance of the medical device with the essential requirements regarding clinical efficacy and clinical safety. The effect of the substances contained in the product such as iota-carrageenan, sodium hyaluronate and ectoine has been confirmed in clinical trials.

 The clinical evaluation performed for the medical device confirms the efficacy of Bloxivir.

Yes Bloxivir is intended for adults and for children over one year of age. Parent/guardian supervision is required when used in children.

Both versions have a different applicator, which is properly adjusted to the dedicated site of administering the substance.

The medical device Bloxivir is recommended as additional protection which expands the arsenal of government-recommended preventive measures against flu or Covid-19.

Protective equipment such as masks should be used in accordance with the current epidemiological recommendations of a given country.

Bloxivir can be used both on regular basis (applying a new layer of Bloxivir every 4-5 hours) and ad hoc (applying the product as needed).

According to the classification, the medical device is of "short-term use", ie it is usually intended for continuous use not longer than 30 days. If the product was used continuously (in the case of Bloxivir: application every 4-5 hours within 24 hours’ time period, i.e. about 6 times a day), a 24-hour break is recommended, each time after 30 days of using the product.

No data are available on serious adverse medical events related to the interaction of the device with other drugs.

According to the instructions, the use of the product together with other nasal substances in the case of Bloxivir nasal gel, and oral substances in the case of Bloxivir oral gel should be consulted with a doctor.

According to the instructions, the use of the product together with other nasal substances in the case of Bloxivir nasal gel, and oral substances in the case of Bloxivir oral gel should be consulted with a doctor.

According to the information contained in the instructions, the use of the product together with other nasal substances should be consulted with a doctor.

The device does not affect the ability to drive or use machines.

By supporting the natural protective mechanisms on the nasal mucosa, Bloxivir can also be used supportively in case of allergic inflammation of the nasal mucosa in order to block the penetration of allergens. With fewer allergens entering the cells, the body’s reaction to allergens and thus symptoms can be less severe.